RecombinantVaspin, Human

• Description:

  Vaspin is a cytokine originally identified in visceral adipose tissue of Otsuka Long-Evans Tokushima fatty rats, and the name “Vaspin” is short for visceral adipose tissue-derived serine protease inhibitor. Besides the visceral adipose, Vaspin is also expressed in the skin, hypothalamus, pancreatic islets and stomach, and is shown to exert an anti-inflammatory role by inhibiting several proinflammatory adipokines such as leptin, resistin, and Tumor Necrosis Factor-α. Vaspin also stimulates adiponectin expression and improves insulin sensitivity in mice. Vaspin expression has been shown to decrease with worsening of diabetes and body weight loss. Accordingly, administration of recombinant human Vaspin improved glucose tolerance in diet regulated mice suggesting it as a potential target for obese-related diseases. Recombinant human Vaspin (rhVaspin) produced in E.coli is a single non-glycosylated polypeptide chain containing 394 amino acids. rhVaspin has a molecular mass of 45.1kDa analyzed by reducing SDS-PAGE and is obtained by proprietary chromatographic techniques at GenScript.

• Endotoxin:

  < 0.2 EU/μg, determined by LAL method.

• Purity:

  > 95% by SDS-PAGE and HPLC analyses.

• Bioactivity:

  Bioassay data are not available.

• Reconstitution:

  Reconstituted in ddH2O at 100 μg/mL.

• Molecular Weight:

  45.1 kDa, observed by reducing SDS-PAGE.

• Storage Conditions:

  Lyophilized recombinant human Vaspin (rhVaspin) remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, rhVaspin remains stable up to 2 weeks at 4°C or up to 3 months at -20°C.

• Appearance:

  Sterile Filtered White lyophilized (freeze-dried) powder.

• Formulation:

  Lyophilized after extensive dialysis against PBS.

• Host or Source:

  Escherichia coli.

• Recommended Usage:

  This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. For research use only.

• CAS Number:

  9000-83-3

• AA Sequence:

  LKP SFSPRNYKAL SEVQGWKQRM AAKELARQNM DLGFKLLKKL AFYNPGRNIF LSPLSISTAF SMLCLGAQDS TLDEIKQGFN FRKMPEKDLH EGFHYIIHEL TQKTQDLKLS IGNTLFIDQR LQPQRKFLED AKNFYSAETI LTNFQNLEMA QKQINDFISQ KTHGKINNLI ENIDPGTVML LANYIFFRAR WKHEFDPNVT KEEDFFLEKN SSVKVPMMFR SGIYQVGYDD KLSCTILEIP YQKNITAIFI LPDEGKLKHL EKGLQVDTFS RWKTLLSRRV VDVSVPRLHM TGTFDLKKTL SYIGVSKIFE EHGDLTKIAP HRSLKVGEAV HKAELKMDER GTEGAAGTGA QTLPMETPLV VKIDKPYLLL IYSEKIPSVL FLGKIVNPIG K